CELCUITY INC. - COMMON STOCK

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

14 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

12 Nov 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

07 Nov 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

14 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

07 Aug 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity To Participate in Jefferies Global Healthcare Conference

03 Jun 2024 15:01:00 By Nasdaq GlobeNewswire

Celcuity Announces Pricing of Underwritten Common Stock Offering

30 May 2024 06:36:22 By Nasdaq GlobeNewswire

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

30 May 2024 06:00:01 By Nasdaq GlobeNewswire

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

15 May 2024 15:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

08 May 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

04 Apr 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

27 Mar 2024 15:01:00 By Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

20 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

06 Mar 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

28 Feb 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

22 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

20 Feb 2024 06:05:00 By Nasdaq GlobeNewswire

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

06 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

01 Dec 2023 10:02:45 By Nasdaq GlobeNewswire

Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference

22 Nov 2023 07:05:00 By Nasdaq GlobeNewswire